The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D ac...tivities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.
more
Issue Brief No. 40 provides healthcare professionals with the most relevant treatment guidelines, prevention measures and training material on MVD
It's time to deliver differently.
Accessed: 13.11.2019
This is a basic form for reporting individual cases of plague. It asks for information regarding patient history and the course of the illness. In addition, it offers space for laboratory results, the case status, and epidemiological information.
The roadmap describes the actions needed to
achieve the three development goals for TB
vaccines set by the WHO:
1. A safe, effective and affordable TB vaccine
for adolescents and adults.
2. An affordable TB vaccine for neonates and
infants with improved safety and efficacy.
3. A therapeutic v...accine to improve TB
treatment outcomes
more
В этих новых руководящих принципах рекомендуется использовать упрощенный алгоритм скрининга, основанного на четырех клинических симптомах, для выявления ...иц, которым показана либо ПТИ, либо дальнейшая диагностика для выявления ТБ и других заболеваний.
more
Provisional recommendations May 2014
Source: World Health Organisation
Milestones in the treatment, care and support, Dec 2021
The U.S. President‘s Emergency Plan for AIDS Relief
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.